Molecular MRD is strongly prognostic in patients with <i>NPM1</i>-mutated AML receiving venetoclax-based nonintensive therapyJad Othman, Richard Dillon, Michael J. Austin et al.|Blood|2023Cited by 65
FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AMLJad Othman, Richard Dillon, Panagiotis Kottaridis et al.|Leukemia|2023Cited by 48
Venetoclax–based low intensity therapy in molecular failure of <i>NPM1</i>-mutated AMLCarlos Jiménez‐Chillón, Richard Dillon, Steven Knapper et al.|Blood Advances|2023Cited by 29